Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Onto Innovation Inc ONTO

Technology Semiconductor Equipment & Materials
Onto Innovation Inc. is engaged in the design, development, manufacture and support of metrology and inspection tools for the semiconductor industry. The Company’s products include Automated Metrology Systems; Integrated Metrology Systems; Silicon Wafer All-surface Inspection/Characterization; Macro Defect Inspection; Automated Defect Classification and Pattern Analysis; Yield Analysis; Opaque... see more

Recent & Breaking News (NYSE:ONTO)

Nordic Nanovector: Single-dose Betalutin® Shows Promising Efficacy, Improved Duration of Response and Favourable Safety in Relapsed NHL Patients

Business Wire December 3, 2016

Nordic Nanovector to Present at the Nordic-American Life Sciences Conference in New York

Business Wire December 1, 2016

Nanobiotix : développement global de son produit leader NBTXR3

Business Wire November 28, 2016

NANOBIOTIX Provides Update on Global Development of Lead Product NBTXR3

GlobeNewswire November 28, 2016

Nordic Nanovector ASA – Results for third quarter 2016

Business Wire November 23, 2016

NORDIC NANOVECTOR ASA - RESULTATER FOR TREDJE KVARTAL 2016

Business Wire November 23, 2016

Nanometrics to Participate in 5th Annual Midtown CAP Summit NYC

GlobeNewswire November 17, 2016

Nordic Nanovector ASA: Third Quarter 2016 Results Presentation and Webcast

Business Wire November 16, 2016

NANOBIOTIX : Chiffre d’affaires du troisième trimestre 2016

Business Wire November 15, 2016

Nanobiotix Revenue for Q3 2016

Business Wire November 15, 2016

Nordic Nanovector ASA: Allotment of share options

Business Wire November 15, 2016

Nordic Nanovector appoints Dr Lisa Rojkjaer, MD as Chief Medical Officer

Business Wire November 15, 2016

NANOBIOTIX Presents NBTXR3 Preclinical Data Demonstrating Its Potential Usage as in Situ Vaccine for Cancer at the Society for Immunotherapy of Cancer Annual Meeting

Business Wire November 14, 2016

Nanobiotix présente des résultats précliniques sur une nouvelle utilisation de NBTXR3 comme potentiel vaccin in situ contre le cancer, lors du congrès annuel de la Society for Immunotherapy of Cancer

Business Wire November 14, 2016

Nordic Nanovector to Present at Jefferies 2016 London Healthcare Conference

Business Wire November 14, 2016

Nanobiotix : Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social

Business Wire November 7, 2016

Nordic Nanovector: Safety Review Committee for Nordic Nanovector’s Lymrit 37-01 trial recommends dose escalation to 20 MBq/kg with Betalutin®

Business Wire November 4, 2016

Nordic Nanovector: Results From Preclinical Studies of Betalutin® in Combination with Rituximab in non-Hodgkin Lymphoma Model to Be Presented at ASH

Business Wire November 3, 2016

Nordic Nanovector: Updated Results from Phase 1/2 Trial of Betalutin® in Non-Hodgkin Lymphoma to be Presented at ASH Annual Meeting in December

Business Wire November 3, 2016

Mid-Morning Market Update: Markets Mostly Higher; Mastercard Beats Q3 Views

Benzinga.com  October 28, 2016